The American College of Obstetricians and Gynecologists has recently released updated clinical guidelines on breast cancer screening in women facing average risk.
The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.
In a recent study, researchers examined whether a compound found in soy, isoflavone, could potentially reduce all-cause mortality risk in breast cancer survivors.
In a recent study, researchers sought to determine if cholesterol lowering medication effected survival and recurrence outcomes in patients with breast cancer.